Enhanced circulation half-life of site-specific PEGylated rhG-CSF: Optimization of PEG molecular weight
文献类型：期刊论文
| 作者 | Zhai, Yanqin1,2; Zhao, Yongjiang1,2; Lei, Jiandu1; Su, Zhiguo1; Ma, Guanghui1 |
| 刊名 | JOURNAL OF BIOTECHNOLOGY
 |
| 出版日期 | 2009-07-15 |
| 卷号 | 142期号:3-4页码:259-266 |
| 关键词 | Drug bioavailability Granulocyte colony stimulating factor (G-CSF) Serum half-life Site-specific PEGylation |
| ISSN号 | 0168-1656 |
| 通讯作者 | Lei, JD |
| 英文摘要 | Recombinant human granulocyte colony stimulating factor (rhG-CSF) and its PEGylated product "mono-PEG20-GCSF" have already been widely used for treatment of all kinds of neutropenia. However, I he high required dosage of mono-PEG20-GCSF made it relatively expensive in clinical use. We postulated that an N-terminal site-specific PEGylated rhG-CSF with higher PEG Mw (PEG30 kDa) might be able to achieve longer circulation half-life while retaining its bioactivity, allowing the reduction of dosage for clinical use. rhG-CSF was PEGylated at the N-terminus by 5 kDa, 10 kDa, 20 kDa and 30 kDa methoxypoly(ethylene glycol)-propionaldehyde (niPEG-ALD), and the four PEGylates were compared with respect to reaction, separation, characterization and also in vivo/in vitro activity, results showed that the mPEG-ALD of higher Mw demonstrated better N-terminal site-specific selectivity. separation purity and yield. The production cost and in vitro activity of mono-PEG30-GCSF and rnono-PEG20-GCSF were almost the same, while mono-PEG30-GCSF showed longer in vivo circulation half-life and 60% higher drug bioavailability than mono-PEG20-GCSF Consequently, mono-PEG30-GCSF shall be administered at a lower dosage than mono-PEG20-GCSF while retaining the same therapeutic efficacy. (C) 2009 Elsevier B.V. All rights reserved. |
| WOS标题词 | Science & Technology ; Life Sciences & Biomedicine |
| 类目[WOS] | Biotechnology & Applied Microbiology |
| 研究领域[WOS] | Biotechnology & Applied Microbiology |
| 关键词[WOS] | COLONY-STIMULATING FACTOR ; ION-EXCHANGE CHROMATOGRAPHY ; ACUTE MYELOID-LEUKEMIA ; POLY(ETHYLENE GLYCOL) ; CLINICAL-APPLICATIONS ; INTERFERON ALPHA-2A ; DAILY FILGRASTIM ; PEGFILGRASTIM ; CHEMOTHERAPY ; PROTEINS |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000268823400011 |
| 公开日期 | 2013-12-06 |
| 版本 | 出版稿 |
| 源URL | [http://ir.ipe.ac.cn/handle/122111/6634]  |
| 专题 | 过程工程研究所_生化工程国家重点实验室 |
| 作者单位 | 1.Chinese Acad Sci, Inst Proc Engn, Natl Key Lab Biochem Engn, Beijing 100190, Peoples R China 2.Chinese Acad Sci, Grad Univ, Beijing 100049, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhai, Yanqin,Zhao, Yongjiang,Lei, Jiandu,et al. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: Optimization of PEG molecular weight[J]. JOURNAL OF BIOTECHNOLOGY,2009,142(3-4):259-266. |
| APA | Zhai, Yanqin,Zhao, Yongjiang,Lei, Jiandu,Su, Zhiguo,&Ma, Guanghui.(2009).Enhanced circulation half-life of site-specific PEGylated rhG-CSF: Optimization of PEG molecular weight.JOURNAL OF BIOTECHNOLOGY,142(3-4),259-266. |
| MLA | Zhai, Yanqin,et al."Enhanced circulation half-life of site-specific PEGylated rhG-CSF: Optimization of PEG molecular weight".JOURNAL OF BIOTECHNOLOGY 142.3-4(2009):259-266. |
入库方式： OAI收割
来源：过程工程研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。